Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia
James M Kelvin,Madison L Chimenti,Dan Y Zhang,Evelyn K Williams,Samuel G Moore,Gabrielle M Humber,Travon A Baxter,Lacey A Birnbaum,Min Qui,Henry Zecca,Aashis Thapa,Juhi Jain,Nathan T Jui,Xiaodong Wang,Haian Fu,Yuhong Du,Melissa L Kemp,Wilbur A Lam,Douglas K Graham,Deborah DeRyckere,Erik C Dreaden,James M. Kelvin,Madison L. Chimenti,Dan Y. Zhang,Evelyn K. Williams,Samuel G. Moore,Gabrielle M. Humber,Travon A. Baxter,Lacey A. Birnbaum,Nathan T. Jui,Melissa L. Kemp,Wilbur A. Lam,Douglas K. Graham,Erik C. Dreaden
DOI: https://doi.org/10.1016/j.jconrel.2023.07.045
IF: 11.467
2023-08-16
Journal of Controlled Release
Abstract:Advances in multiagent chemotherapy have led to recent improvements in survival for patients with acute lymphoblastic leukemia (ALL); however, a significant fraction do not respond to frontline chemotherapy or later relapse with recurrent disease, after which long-term survival rates remain low. To develop new, effective treatment options for these patients, we conducted a series of high-throughput combination drug screens to identify chemotherapies that synergize in a lineage-specific manner with MRX-2843, a small molecule dual MERTK and FLT3 kinase inhibitor currently in clinical testing for treatment of relapsed/refractory leukemias and solid tumors. Using experimental and computational approaches, we found that MRX-2843 synergized strongly— and in a ratio-dependent manner —with vincristine to inhibit both B-ALL and T-ALL cell line expansion. Based on these findings, we developed multiagent lipid nanoparticle formulations of these drugs that not only delivered defined drug ratios intracellularly in T-ALL, but also improved anti-leukemia activity following drug encapsulation. Synergistic and additive interactions were recapitulated in primary T-ALL patient samples treated with MRX-2843 and vincristine nanoparticle formulations, suggesting their clinical relevance. Moreover, the nanoparticle formulations reduced disease burden and prolonged survival in an orthotopic murine xenograft model of early thymic precursor T-ALL (ETP-ALL), with both agents contributing to therapeutic activity in a dose-dependent manner. In contrast, nanoparticles containing MRX-2843 alone were ineffective in this model. Thus, MRX-2843 increased the sensitivity of ETP-ALL cells to vincristine in vivo. In this context, the additive particles, containing a higher dose of MRX-2843, provided more effective disease control than the synergistic particles. In contrast, particles containing an even higher, antagonistic ratio of MRX-2843 and vincristine were less effective. Thus, both the drug dose and the ratio-dependent interaction between MRX-2843 and vincristine significantly impacted therapeutic activity in vivo. Together, these findings present a systematic approach to high-throughput combination drug screening and multiagent drug delivery that maximizes the therapeutic potential of combined MRX-2843 and vincristine in T-ALL and describe a novel translational agent that could be used to enhance therapeutic responses to vincristine in patients with T-ALL. This broadly generalizable approach could also be applied to develop other constitutively synergistic combination products for the treatment of cancer and other diseases.
pharmacology & pharmacy,chemistry, multidisciplinary